Osteoporosis Prevention Tips for Women

Osteoporosis is a highly prevalent disease among women; half of women over 50 will break a bone due to osteoporosis, according to the National Osteoporosis Foundation. Characterized by thinning of the bone that leads to fractures, the condition is caused by the fact that the body stops rebuilding bone fast enough to replace degeneration as we age. This generally begins in the mid 30's, but it usually doesn't pose any risks until women reach menopause. Men also suffer from osteoporosis, but usually at a much older age.

When a woman hits menopause, her shares of the hormone estrogen decline dramatically. This hormone is responsible for preventing the breakdown of women's bones. Any situation indicating low estrogen levels, including lack of a menstrual period before a woman reaches a natural age for menopause, is a risk factor for osteoporosis. Combined with the sudden drop in estrogen, women also have smaller, thinner bones than men generally. It's important for women to focus on preventative methods.

Below are several measures you can take to help prevent osteoporosis.

1) Take calcium and vitamin D supplements, the latter of which helps the body absorb calcium.

2) Do exercise that subjects the bones to weight-bearing, which encourages rebuilding.

3) Increase your intake of foods that contain calcium. Dairy products aren't the only foods that contain calcium. Kale, collard greens, tempeh, fortified orange juice, turnip greens and blackstrap molasses are all potent sources.

4) Avoid excess salt consumption. Aside from increasing your risk of heart disease, a Japanese study, available at http://www.sciencedaily.com/releases/2013/06/130617110931.htm, found that very high sodium intake correlates with bone fracture risk.

5) Research is currently inconclusive, but the results of some studies suggest that fructooligosaccharides, aside from being fun to say, are good for your bones. These non-digestible carbs may increase your body's ability to absorb calcium. They're found in chicory root, onions, tomatoes, asparagus and wheat.

6) Take steps to avoid insulin resistance, the hallmark of type 2 diabetes. Insulin resistance is common among people who are overweight. A study, found at http://www.sciencedaily.com/releases/2013/06/130617110715.htm, determined diabetics to have weaker bones than non-diabetics. The best ways to prevent type 2 diabetes are to exercise and eat well, maintaining a healthy weight.

7) If you're too young to be experiencing menopause but have stopped getting your period (or never started), see a doctor. If no dysfunction is found, you may wish to begin using birth control to regulate your hormones. The extra estrogen will help keep your bones strong.

As with most health conditions, preventing osteoporosis involves eating right and exercising. Taking simple steps now to prevent this and other conditions will help you live longer and better as you age.

Solutions specific to pregnancy back pain, weight loss and other women specific issues. Please ask questions, give comments or stories related to this article submission for women's issues.

View the original article here

Children who use gestures tend to perform better on cognitive tasks

Main Category: Psychology / Psychiatry
Also Included In: Pediatrics / Children's Health
Article Date: 30 Jul 2013 - 0:00 PDT Current ratings for:
Children who use gestures tend to perform better on cognitive tasks

In the first study of its kind, SF State researchers have shown that younger children who use gestures outperform their peers in a problem-solving task.

The task itself is relatively simple -- sorting cards printed with colored shapes first by color, and then by shape. But the switch from color to shape can be tricky for children younger than 5, says Professor of Psychology Patricia Miller.

In a new study due to be published in the August, 2013 issue of Developmental Psychology, Miller and SF State graduate student Gina O'Neill found that young children who gesture are more likely to make the mental switch and group the shapes accurately.

In fact, gesturing seemed to trump age when it came to the sorting performance of the children, who ranged from 2 and a half years old to 5 years old. In the color versus shape task, as well as one that asked children to sort pictures based on size and spatial orientation, younger children who gestured often were more accurate in their choices than older children who gestured less. The children's gestures included rotating their hands to show the orientation of a card or using their hands to illustrate the image on the card, for example gesturing the shape of rabbits' ears for a card depicting a rabbit.

"Gina and I were surprised by the strength of the effect. Still, the findings are consistent with a growing body of research showing that mind and body work closely together in early cognitive development," Miller said.

"The findings are a reminder of how strong individual differences are among children of a particular age," she added. "Certain 3-year-olds look like typical 4-year-olds. This likely reflects an interaction of natural talent and particular experiences -- both nature and nurture, as usual."

There is a growing body of research that suggests gesturing may play a significant role in the processes that people use to solve a problem or achieve a goal. These processes include holding information in memory, keeping the brain from choosing a course too quickly and being flexible in adding new or different information to handle a task.

Studies have shown that gesturing can help older children learn new math concepts, for example. "Really, though, there is evidence that gesturing helps with difficult cognitive tasks at any age," Miller said. "Even we adults sometimes gesture when we're trying to organize our tax receipts or our closets. When our minds are overflowing we let our hands take on some of the cognitive load."

O'Neill and Miller observed the children's spontaneous gestures as they performed the tasks, as well as gestures they were encouraged to make to explain their sorting choices. Both kinds of gestures were counted in comparing high and low gesturing children.

Children who did a lot of gesturing did better at the sorting task than those who didn't gesture as much -- even when they did not use gesturing during the task itself, the researchers found. This makes it difficult to determine whether it's the gesturing itself that helps the children perform the task, or whether children who use a lot of gestures are simply at a more advanced cognitive level than their peers. It is a question that Miller hopes to answer in further studies.

Miller said there is "quite a bit of evidence now that gestures can help children think," perhaps by helping the brain keep track of relevant information or by helping the brain reflect on the possibilities contained within a task. "In my opinion, children shouldn't be discouraged from gesturing when they want to gesture during learning," she said. "Adults sometimes -- appropriately -- say to children, 'use your words,' but some children may think this applies to all situations."

Article adapted by Medical News Today from original press release. Click 'references' tab above for source.
Visit our psychology / psychiatry section for the latest news on this subject.

The study, "A Show of Hands: Relations between Young Children's Gesturing and Executive Function," will be published in the August, 2013 issue of the journal Developmental Psychology.

San Francisco State University

Please use one of the following formats to cite this article in your essay, paper or report:

MLA

San Francisco State University. "Children who use gestures tend to perform better on cognitive tasks." Medical News Today. MediLexicon, Intl., 30 Jul. 2013. Web.
30 Jul. 2013. APA

Please note: If no author information is provided, the source is cited instead.

'Children who use gestures tend to perform better on cognitive tasks'

Please note that we publish your name, but we do not publish your email address. It is only used to let you know when your message is published. We do not use it for any other purpose. Please see our privacy policy for more information.

If you write about specific medications or operations, please do not name health care professionals by name.

All opinions are moderated before being included (to stop spam). We reserve the right to amend opinions where we deem necessary.

Contact Our News Editors

For any corrections of factual information, or to contact the editors please use our feedback form.

Please send any medical news or health news press releases to:

Note: Any medical information published on this website is not intended as a substitute for informed medical advice and you should not take any action before consulting with a health care professional. For more information, please read our terms and conditions.

View the original article here

Children's exercise: Hour a day 'not enough'

Please note that we publish your name, but we do not publish your email address. It is only used to let you know when your message is published. We do not use it for any other purpose. Please see our privacy policy for more information.

If you write about specific medications or operations, please do not name health care professionals by name.

All opinions are moderated before being included (to stop spam). We reserve the right to amend opinions where we deem necessary.

View the original article here

FDA approves treatment for major depressive disorder in adults

Main Category: Depression
Also Included In: Regulatory Affairs / Drug Approvals
Article Date: 30 Jul 2013 - 2:00 PDT Current ratings for:
FDA approves treatment for major depressive disorder in adults

Forest Laboratories, Inc. announced that FETZIMA (levomilnacipran extended-release capsules) was approved by the FDA for the treatment of Major Depressive Disorder (MDD) in adults. MDD, also generally known as depression, affects almost 16 million adults in the United States every year. MDD is a serious medical condition, and despite available options, people with MDD often struggle to find a treatment that works for them -- so FDA approval of FETZIMA may be important for adults living with MDD.

FETZIMA is the most recent addition to Forest's growing mental health portfolio. For more than 15 years, Forest Laboratories has been driven by a focus on addressing unmet needs in the area of mental health. Forest's franchise now includes two marketed products for MDD:

VIIBRYD® (vilazodone HCl), launched in 2011, is the first and only selective serotonin reuptake inhibitor (SSRI) and 5-HT1A partial receptor agonist and is indicated for the treatment of adults with MDD.And now FETZIMA, approved in July 2013, is a once-daily serotonin and norepinephrine reuptake inhibitor (SNRI) indicated for MDD in adults.Please see Important Safety Information, including Boxed Warning, for FETZIMA and VIIBRYD below.

Together, these products reflect Forest's research-driven approach toward identifying and developing a range of treatment options for the millions of Americans who live with MDD.

In three placebo-controlled, pivotal Phase III studies of adult patients with MDD, statistically significant and clinically meaningful improvement in depressive symptoms was demonstrated across three FETZIMA dosage strengths of 40, 80, and 120 mg once daily compared with placebo as measured by the Montgomery Åsberg Depression Rating Scale (MADRS) total score (primary endpoint). FETZIMA also demonstrated superiority over placebo as measured by improvement in the Sheehan Disability Scale (SDS) functional impairment total score (secondary endpoint).

FETZIMA is a serotonin and norepinephrine reuptake inhibitor (SNRI) indicated for the treatment of Major Depressive Disorder (MDD) in adults.

FETZIMA is not approved for the management of fibromyalgia. The efficacy and safety of FETZIMA for the management of fibromyalgia have not been established.

WARNING: SUICIDAL THOUGHTS AND BEHAVIORS

Antidepressants increased the risk of suicidal thoughts and behavior in children, adolescents, and young adults in short-term studies. These studies did not show an increase in the risk of suicidal thoughts and behavior with antidepressant use in patients over age 24; there was a reduction in risk with antidepressant use in patients aged 65 and older.

In patients of all ages who are started on antidepressant therapy, monitor closely for worsening, and for emergence of suicidal thoughts and behaviors. Advise families and caregivers of the need for close observation and communication with the prescriber. FETZIMA is not approved for use in pediatric patients.

FETZIMA is contraindicated in patients with a hypersensitivity to levomilnacipran, milnacipran HCl, or to any excipient in the formulation.The use of MAOIs intended to treat psychiatric disorders with FETZIMA or within 7 days of stopping treatment with FETZIMA is contraindicated due to an increased risk of serotonin syndrome. The use of FETZIMA within 14 days of stopping an MAOI intended to treat psychiatric disorders is also contraindicated.Starting FETZIMA in a patient who is being treated with MAOIs such as linezolid or intravenous methylene blue is also contraindicated due to an increased risk of serotonin syndrome.Do not use FETZIMA in patients with uncontrolled narrow-angle glaucoma. All patients being treated with antidepressants should be monitored appropriately and observed closely for clinical worsening, suicidality, and unusual changes in behavior, especially during the first few months of treatment and when increasing or decreasing the dose. Consider changing the therapeutic regimen, including possibly discontinuing the medication, in patients whose depression is persistently worse or includes symptoms of anxiety, agitation, panic attacks, insomnia, irritability, hostility, aggressiveness, impulsivity, akathisia, hypomania, mania, or suicidality that are severe, abrupt in onset, or were not part of the patient's presenting symptoms. Families and caregivers of patients being treated with antidepressants should be alerted about the need to monitor patients daily. Prescriptions for FETZIMA should be written for the smallest quantity of capsules consistent with good patient management, in order to reduce the risk of overdose.Serotonin Syndrome: The development of a potentially life-threatening serotonin syndrome has been reported with SNRIs and SSRIs both when taken alone, but especially when co-administered with other serotonergic agents (including triptans, tricyclic antidepressants, fentanyl, lithium, tramadol, tryptophan, buspirone, and St. John's Wort) and with drugs that impair metabolism of serotonin (in particular, MAOIs, both those intended to treat psychiatric disorders and also others, such as linezolid and intravenous methylene blue). Symptoms of serotonin syndrome may include mental status changes (eg, agitation, hallucinations, delirium, and coma), autonomic instability (eg, tachycardia, labile blood pressure, diaphoresis, flushing, hyperthermia), neuromuscular symptoms (eg, tremor, rigidity, myoclonus, hyperreflexia, incoordination), seizures, and/or gastrointestinal symptoms. If symptoms of serotonin syndrome occur, discontinue FETZIMA and initiate supportive treatment. If concomitant use of FETZIMA with other serotonergic drugs is clinically warranted, patients should be aware of a potential increased risk for serotonin syndrome, particularly during treatment initiation and dose increases.SNRIs, including FETZIMA, have been associated with increases in blood pressure. Blood pressure should be measured prior to initiating treatment and periodically throughout FETZIMA treatment. Pre-existing hypertension should be controlled before initiating treatment with FETZIMA. For patients who experience a sustained increase in blood pressure, discontinuation or other appropriate medical intervention should be considered.SNRIs including FETZIMA have been associated with an increase in heart rate. Heart rate should be measured prior to initiating treatment and periodically throughout FETZIMA treatment. Pre-existing tachyarrhythmias and other cardiac disease should be treated before starting therapy with FETZIMA. For patients who experience a sustained increase in heart rate, discontinuation or other appropriate medical intervention should be considered.SSRIs and SNRIs, including FETZIMA, may increase the risk of bleeding events, some serious. Concomitant use of aspirin, warfarin, NSAIDs and other anticoagulants may add to this risk.Mydriasis has been reported in association with SNRIs including FETZIMA; therefore, FETZIMA should be used with caution in patients with controlled narrow-angle glaucoma. Patients with raised intraocular pressure should be monitored. DO NOT use FETZIMA in patients with uncontrolled narrow-angle glaucoma.SNRIs, including FETZIMA, can affect urethral resistance. Caution is advised when using FETZIMA in patients prone to obstructive urinary disorders.Symptoms of mania/hypomania were reported in 0.2% of FETZIMA-treated patients and 0.2% of placebo-treated patients in clinical studies. As with all antidepressants, FETZIMA should be used cautiously in patients with a history or family history of bipolar disorder, mania or hypomania. Prior to initiating treatment with FETZIMA, patients should be adequately screened to determine if they are at risk for bipolar disorder. FETZIMA is not approved for use in treating bipolar depression.FETZIMA should be prescribed with caution in patients with a seizure disorder.Discontinuation symptoms, some serious, have been reported with discontinuation of serotonergic antidepressants such as FETZIMA. Gradual dose reduction is recommended, instead of abrupt discontinuation, whenever possible. Monitor patients when discontinuing FETZIMA. If intolerable symptoms occur following a dose decrease or upon discontinuation of treatment, consider resuming the previously prescribed dose and decreasing the dose at a more gradual rate.Advise patients that if they are treated with diuretics or are otherwise volume depleted, or are elderly, they may be at greater risk of developing hyponatremia while taking FETZIMA. Although no cases of hyponatremia resulting from FETZIMA treatment were reported in the clinical studies, hyponatremia has occurred as a result of treatment with SSRIs and SNRIs. FETZIMA should be discontinued in patients with symptomatic hyponatremia and appropriate medical intervention should be instituted.

The most commonly observed adverse reactions in MDD patients treated with FETZIMA in placebo-controlled studies (incidence =5% and at least twice the rate of placebo) were: nausea, constipation, hyperhidrosis, heart rate increased, erectile dysfunction, tachycardia, vomiting, and palpitations.

Please also see full Prescribing Information for FETZIMA.

WARNING: SUICIDALITY AND ANTIDEPRESSANT DRUGS

Antidepressants increased the risk compared to placebo of suicidal thinking and behavior (suicidality) in children, adolescents, and young adults in short-term studies of Major Depressive Disorder (MDD) and other psychiatric disorders. Anyone considering the use of VIIBRYD or any other antidepressant in a child, adolescent, or young adult must balance this risk with the clinical need. Short-term studies did not show an increase in the risk of suicidality with antidepressants compared to placebo in adults beyond age 24; there was a reduction in risk with antidepressants compared to placebo in adults aged 65 and older. Depression and certain other psychiatric disorders are themselves associated with increases in the risk of suicide. Patients of all ages who are started on antidepressant therapy should be monitored appropriately and observed closely for clinical worsening, suicidality, or unusual changes in behavior. Families and caregivers should be advised of the need for close observation and communication with the prescriber. VIIBRYD is not approved for use in pediatric patients.

Serotonin Syndrome and MAOIs: Do not use MAOIs intended to treat psychiatric disorders with VIIBRYD or within 14 days of stopping treatment with VIIBRYD. Do not use VIIBRYD within 14 days of stopping an MAOI intended to treat psychiatric disorders. In addition, do not start VIIBRYD in a patient who is being treated with linezolid or intravenous methylene blue.

All patients treated with antidepressants should be monitored appropriately and observed closely for clinical worsening, suicidality, and unusual changes in behavior, especially during the first few months of treatment and when changing the dose. Consider changing the therapeutic regimen, including possibly discontinuing the medication, in patients whose depression is persistently worse or includes symptoms of anxiety, agitation, panic attacks, insomnia, irritability, hostility, aggressiveness, impulsivity, akathisia, hypomania, mania, or suicidality that are severe, abrupt in onset, or were not part of the patient's presenting symptoms. Families and caregivers of patients being treated with antidepressants should be alerted about the need to monitor patients daily. Prescriptions for VIIBRYD should be written for the smallest quantity of tablets consistent with good patient management, in order to reduce the risk of overdose.

Serotonin Syndrome: The development of a potentially life-threatening serotonin syndrome has been reported with SNRIs and SSRIs, including VIIBRYD, both when taken alone, but especially when co-administered with other serotonergic agents (including triptans, tricyclic antidepressants, fentanyl, lithium, tramadol, tryptophan, buspirone, and St. John's Wort) and with drugs that impair metabolism of serotonin (in particular, MAOIs, both those intended to treat psychiatric disorders and also others, such as linezolid and intravenous methylene blue). Symptoms of serotonin syndrome may include mental status changes (eg, agitation, hallucinations, delirium, and coma), autonomic instability (eg, tachycardia, labile blood pressure, diaphoresis, flushing, hyperthermia), neuromuscular symptoms (eg, tremor, rigidity, myoclonus, hyperreflexia, incoordination), seizures, and/or gastrointestinal symptoms. If symptoms of serotonin syndrome occur, discontinue VIIBRYD and initiate supportive treatment. If concomitant use of VIIBRYD with other serotonergic drugs is clinically warranted, patients should be aware of a potential increased risk for serotonin syndrome, particularly during treatment initiation and dose increases. Patients should be monitored for the emergence of serotonin syndrome.

Like other antidepressants, VIIBRYD should be prescribed with caution in patients with a seizure disorder.

The use of drugs that interfere with serotonin reuptake, including VIIBRYD, may increase the risk of bleeding events. Patients should be cautioned about the risk of bleeding associated with the concomitant use of VIIBRYD and NSAIDs, aspirin, warfarin, or other drugs that affect coagulation or bleeding.

Symptoms of mania/hypomania were noted in 0.1% of patients treated with VIIBRYD in clinical studies. As with all antidepressants, VIIBRYD should be used cautiously in patients with a history or family history of bipolar disorder, mania, or hypomania.

Prior to initiating treatment with an antidepressant, patients with depressive symptoms should be adequately screened to determine if they are at risk for bipolar disorder. VIIBRYD is not approved for use in treating bipolar depression.

Discontinuation symptoms have been reported with discontinuation of serotonergic drugs such as VIIBRYD. Gradual dose reduction is recommended, instead of abrupt discontinuation, whenever possible. Monitor patients when discontinuing VIIBRYD. If intolerable symptoms occur following a dose decrease or upon discontinuation of treatment, consider resuming the previously prescribed dose and decreasing the dose at a more gradual rate.

Advise patients that if they are treated with diuretics, or are otherwise volume depleted, or are elderly, they may be at greater risk of developing hyponatremia while taking VIIBRYD. Although no cases of hyponatremia resulting from VIIBRYD treatment were reported in the clinical studies, hyponatremia has occurred as a result of treatment with SSRIs and SNRIs. Discontinuation of VIIBRYD in patients with symptomatic hyponatremia and appropriate medical intervention should be instituted.

The most commonly observed adverse reactions in MDD patients treated with VIIBRYD in placebo-controlled studies (incidence =5% and at least twice the rate of placebo) were: diarrhea (28% vs 9%), nausea (23% vs 5%), insomnia (6% vs 2%), and vomiting (5% vs 1%).

Please also see full Prescribing Information for VIIBRYD.

Article adapted by Medical News Today from original press release. Source:

Forest Laboratories

Visit our depression section for the latest news on this subject. Please use one of the following formats to cite this article in your essay, paper or report:

MLA

Laboratories, Forest. "FDA approves treatment for major depressive disorder in adults." Medical News Today. MediLexicon, Intl., 30 Jul. 2013. Web.
30 Jul. 2013. APA

Please note: If no author information is provided, the source is cited instead.

'FDA approves treatment for major depressive disorder in adults'

Please note that we publish your name, but we do not publish your email address. It is only used to let you know when your message is published. We do not use it for any other purpose. Please see our privacy policy for more information.

If you write about specific medications or operations, please do not name health care professionals by name.

All opinions are moderated before being included (to stop spam). We reserve the right to amend opinions where we deem necessary.

Contact Our News Editors

For any corrections of factual information, or to contact the editors please use our feedback form.

Please send any medical news or health news press releases to:

Note: Any medical information published on this website is not intended as a substitute for informed medical advice and you should not take any action before consulting with a health care professional. For more information, please read our terms and conditions.

View the original article here

Female deaths much less likely to be reported to coroner in England and Wales, UK

Main Category: Women's Health / Gynecology
Article Date: 30 Jul 2013 - 0:00 PDT Current ratings for:
Female deaths much less likely to be reported to coroner in England and Wales, UK

Doctors in England and Wales are much less likely to report a woman's death to a coroner than they are a man's, reveals research published online in the Journal of Clinical Pathology.

Furthermore, women's deaths are less likely to proceed to an inquest, and those that do are less likely to result in a verdict of "unnatural" death than men's, with some coroners particularly likely to favour a verdict according to the sex of the deceased, the research shows.

The authors analysed figures from the Ministry of Justice on the numbers and proportions of deaths reported to all 98 coroners, in each of the 114 jurisdictions in England and Wales, between 2001 and 2010.

These figures were then set in the context of official national statistics on the number of deaths registered in England and Wales over the same period.

Doctors are not obliged to report a death to a coroner, and the legal duty to hold an inquest resides with the coroner, usually prompted by a death in unnatural or violent circumstances, or when the death is sudden, of unknown cause, or happens in prison.

The analysis of the figures showed that coroner reporting rates varied widely across England and Wales.

Plymouth and South West Devon topped the league table, with 87% of registered deaths reported to the coroner between 2001 and 2010, while Stamford in Lincolnshire came bottom, with only 12% of deaths reported to the coroner.

There were no obvious explanations to account for such wide differences, which remained stable throughout the decade, suggesting that local demographics or medico-legal practice had a part to play, say the authors.

Similarly, coroners varied widely in their use of verdicts, which again remained consistent over time, the analysis showed. This is likely to reflect the personal decision making style of the coroner rather than any local patterns in deaths, say the authors.

But when they looked at reporting rates according to the sex of the dead person, a striking gender divide emerged.

While jurisdictions with high reporting rates for men also had high reporting rates for women, and vice versa, male deaths were 26% more likely to be reported to the coroner than female deaths.

Higher reporting rates for men were common across all jurisdictions in England and Wales, and in some areas male deaths were 48% more likely to be reported.

Not only were female deaths less likely to be reported, but they were also less likely to proceed to an inquest.

Female deaths were half as likely to proceed to an inquest as men's, with just 8% going to this stage compared with 16% of all male deaths. And even when female deaths did get an inquest, they were more likely to be given a verdict of natural causes than men (28% compared with 22%).

Among verdicts of unnatural deaths, men were overrepresented in occupational diseases and suicide while women were overrepresented in narrative verdicts - where cause of death is given in the form of a narrative rather than as a single "short form" definition - and accidents, implying that sex of the deceased influences the verdict, say the authors.

Furthermore, some coroners were "gendered," in their approach to inquest verdicts, and more likely to favour a particular verdict when dealing with a death, according to the gender of the deceased.

The government is currently reforming the death certification process in a bid to strengthen arrangements and improve the quality and accuracy of causes of death, but there are some concerns that the move will prompt a fall in deaths reported to the coroner from the present national average of 46% to around 35%, say the authors.

Article adapted by Medical News Today from original press release. Click 'references' tab above for source.
Visit our women's health / gynecology section for the latest news on this subject. Please use one of the following formats to cite this article in your essay, paper or report:

MLA

BMJ. "Female deaths much less likely to be reported to coroner in England and Wales, UK." Medical News Today. MediLexicon, Intl., 30 Jul. 2013. Web.
30 Jul. 2013. APA

Please note: If no author information is provided, the source is cited instead.

'Female deaths much less likely to be reported to coroner in England and Wales, UK'

Please note that we publish your name, but we do not publish your email address. It is only used to let you know when your message is published. We do not use it for any other purpose. Please see our privacy policy for more information.

If you write about specific medications or operations, please do not name health care professionals by name.

All opinions are moderated before being included (to stop spam). We reserve the right to amend opinions where we deem necessary.

Contact Our News Editors

For any corrections of factual information, or to contact the editors please use our feedback form.

Please send any medical news or health news press releases to:

Note: Any medical information published on this website is not intended as a substitute for informed medical advice and you should not take any action before consulting with a health care professional. For more information, please read our terms and conditions.

View the original article here

Happiness is expressed in your genes

Featured Article
Academic Journal
Main Category: Genetics
Also Included In: Psychology / Psychiatry
Article Date: 30 Jul 2013 - 8:00 PDT Current ratings for:
Happiness is expressed in your genes

"If you're happy and you know it..." Researchers have studied how "positive psychology" impacts gene expression in humans.

Steven Cole from UCLA led a team who examined the human genome - some 21,000 genes - in light of two different classifications of happiness:

Eudaimonic well-being - the type of happiness associated with having "a deep sense of purpose and meaning in life"Hedonic well-being - the type of happiness associated with unmitigated self-gratification.

The researchers assessed 80 healthy adults for hedonic and eudaimonic well-being, and they took into account potential negative psychological and behavioral elements. They then drew blood from the participants and mapped the varying biological effects of either hedonic or eudaimonic well-being, using a gene-expression profile known as conserved transcriptional response to adversity (CTRA).

The CTRA is a shift associated with an increase of inflammation and a decrease in antiviral activities with the genes. This response, notes Steven Cole, probably evolved to aid the immune system in the wake of changing patterns, such as microbial threats accompanying shifting socio-environmental conditions - for example, social conflict and contact.

The study showed that people who had high levels of eudaimonic well-being had low levels of inflammatory gene expression and exhibited a strong expression of antiviral and antibody genes.

The opposite was true for people who had high levels of hedonic well-being - giving high inflammation and low antiviral/antibody expression.

Steven Cole and his team have been studying how the human genome reacts to negative psychology, including stress, misery and fear, for the last 10 years.

He notes that "in contemporary society and our very different environment, chronic activation by social or symbolic threats can promote inflammation and cause cardiovascular, neurodegenerative and other diseases, and can impair resistance to viral infections."

This recent study, which was published in the journal Proceedings of the National Academy of Sciences is the first of its kind to study positive psychology effects on gene expression.

Although the study participants with eudaimonic well-being had positive gene profiles in their immune cells and those with hedonic well-being had more adverse profiles, Cole notes that both groups did not feel any different.

Both groups had similar levels of positivity but their genomes responded quite differently.

Cole adds:

"What this study tells us is that doing good and feeling good have very different effects on the human genome, even though they generate similar levels of positive emotion.

Apparently, the human genome is much more sensitive to different ways of achieving happiness than are conscious minds."

A recent study located a happiness gene, which researchers say affects people's satisfaction with life.

Written by Marie Ellis

Copyright: Medical News Today
Not to be reproduced without permission of Medical News Today Visit our genetics section for the latest news on this subject.

“A functional genomic perspective on human well-being,” Steven Cole, et al., Proceedings of the National Academy of Sciences, published online 29 July 2013.

Please use one of the following formats to cite this article in your essay, paper or report:

MLA

Ellis, Marie. "Happiness is expressed in your genes." Medical News Today. MediLexicon, Intl., 30 Jul. 2013. Web.
30 Jul. 2013. APA

Please note: If no author information is provided, the source is cited instead.

'Happiness is expressed in your genes'

Please note that we publish your name, but we do not publish your email address. It is only used to let you know when your message is published. We do not use it for any other purpose. Please see our privacy policy for more information.

If you write about specific medications or operations, please do not name health care professionals by name.

All opinions are moderated before being included (to stop spam). We reserve the right to amend opinions where we deem necessary.

Contact Our News Editors

For any corrections of factual information, or to contact the editors please use our feedback form.

Please send any medical news or health news press releases to:

Note: Any medical information published on this website is not intended as a substitute for informed medical advice and you should not take any action before consulting with a health care professional. For more information, please read our terms and conditions.

View the original article here

High blood pressure risk and playing college football linked

Main Category: Hypertension
Also Included In: Sports Medicine / Fitness
Article Date: 30 Jul 2013 - 2:00 PDT Current ratings for:
High blood pressure risk and playing college football linked

College football players, especially linemen, may develop high blood pressure over the course of their first season, according to a small study in the American Heart Association's journal Circulation.

Researchers documented higher blood pressure levels among 113 first-year college players. Only one player had already been diagnosed with hypertension before the season and 27 percent had a family history of hypertension. At post-season, researchers noted:

47 percent of players were considered pre-hypertensive, while 14 percent had stage 1 hypertension.

While previous studies indicate blood pressure elevation during adolescence and young adulthood can increase heart disease and heart-related death later in life, the unique findings of this study suggest early careful monitoring of young football players and timely treatment could improve their heart health later in life.

"High blood pressure is not a good thing at any point in life, but especially during the first two decades," said the study's senior investigator, Aaron L. Baggish, M.D.

"The findings shouldn't scare players," said Baggish, associate director of the Cardiovascular Performance Program at Massachusetts General Hospital. "The earlier in life we can identify and begin treating it the better, and identifying special at-risk groups, like these players, is essential."

From 2006-11, researchers at Massachusetts General Hospital, Harvard Medical School, and Harvard Department of Athletics tracked blood pressure changes among players on the Harvard University team, before and after their first season. Researchers also examined changes in endurance-trained competitive rowers, but found no corresponding increase in blood pressure, suggesting the phenomenon may be related to periodic episodes of intense exertion such as football, Baggish said.

Overall, blood pressure levels averaged 116/64 millimeters of mercury (mm Hg) - which is normal - before the season, but afterward rose to an average 125/66 mm Hg, which is pre-hypertensive.

Players on the offensive or defensive line who gain weight during the season and have a family history of high blood pressure were most likely to have post-season hypertension.

Researchers also noted structural changes in players' left ventricle, the heart's main pumping chamber, which can be a potential indicator of worsening heart health since it can grow thicker if the chamber is overworked. In this study, left ventricle thickening (left ventricular hypertrophy) was more prevalent among football players than endurance athletes, and it was significantly greater among linemen.

"Importantly, left ventricular hypertrophy among football players was strongly associated with resting blood pressure suggesting that heart remodeling in some athletes may be due to what happens off the playing field," he said.

"Considering the popularity of football in the United States, I believe this knowledge of an association with enhanced prevalence of prehypertension and stage 1 hypertension after one season in some players is extremely important," said American Heart Association spokesperson Ernesto Schiffrin, M.D., Ph.D., who is not affiliated with the study. "However, the study should not be interpreted to mean that playing football causes hypertension. Instead, it suggests increased surveillance particularly in those most susceptible: those with a family history of hypertension or playing on the offensive or defensive line."

Professional football players tend to have higher rates of both hypertension and premature death from heart disease, especially linemen, Baggish noted. He and his colleagues are continuing to monitor players identified as at-risk to gain a better understanding of hypertension and heart disease, if and when it develops, as they age.

Article adapted by Medical News Today from original press release. Click 'references' tab above for source.
Visit our hypertension section for the latest news on this subject.

Article: "Blood Pressure and Left Ventricular Hypertrophy During American-Style Football Participation" Rory B. Weiner, MD; Francis Wang, MD; Stephanie K. Isaacs, BS; Rajeev Malhotra, MD; Brant Berkstresser, MS, ATC; Jonathan H. Kim, MD; Adolph M. Hutter Jr, MD; Michael H. Picard, MD; Thomas J. Wang, MD; Aaron L. Baggish, MD. doi: 10.1161/?CIRCULATIONAHA.113.003522. Author disclosures are on the manuscript.

Editorial: "Tackling Cardiovascular Health Risks in College Football Players" Gary J. Balady, MD; Jonathan A. Drezner, MD, doi: 10.1161/?CIRCULATIONAHA.113.004039

The American Heart Association funded the study.

American Heart Association

Please use one of the following formats to cite this article in your essay, paper or report:

MLA

American Heart Association. "High blood pressure risk and playing college football linked." Medical News Today. MediLexicon, Intl., 30 Jul. 2013. Web.
30 Jul. 2013. APA

Please note: If no author information is provided, the source is cited instead.

'High blood pressure risk and playing college football linked'

Please note that we publish your name, but we do not publish your email address. It is only used to let you know when your message is published. We do not use it for any other purpose. Please see our privacy policy for more information.

If you write about specific medications or operations, please do not name health care professionals by name.

All opinions are moderated before being included (to stop spam). We reserve the right to amend opinions where we deem necessary.

Contact Our News Editors

For any corrections of factual information, or to contact the editors please use our feedback form.

Please send any medical news or health news press releases to:

Note: Any medical information published on this website is not intended as a substitute for informed medical advice and you should not take any action before consulting with a health care professional. For more information, please read our terms and conditions.

View the original article here